Kura Oncology, Inc. (KURA)
7.77
+0.34
(+4.58%)
USD |
NASDAQ |
Nov 13, 16:00
7.88
+0.11
(+1.42%)
After-Hours: 19:59
Kura Oncology Enterprise Value : 247.59M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 247.59M |
| November 12, 2026 | 216.35M |
| November 11, 2026 | 243.91M |
| November 10, 2026 | 229.21M |
| November 09, 2026 | 229.21M |
| November 06, 2026 | 201.65M |
| November 05, 2026 | 158.47M |
| November 04, 2026 | 232.89M |
| November 03, 2026 | 441.44M |
| November 02, 2026 | 433.17M |
| October 30, 2026 | 476.35M |
| October 29, 2026 | 503.91M |
| October 28, 2026 | 518.61M |
| October 27, 2026 | 443.28M |
| October 26, 2026 | 417.55M |
| October 23, 2026 | 416.63M |
| October 22, 2026 | 439.60M |
| October 21, 2026 | 441.44M |
| October 20, 2026 | 450.63M |
| October 19, 2026 | 393.67M |
| October 16, 2026 | 367.94M |
| October 15, 2026 | 424.90M |
| October 14, 2026 | 416.63M |
| October 13, 2026 | 436.85M |
| October 12, 2026 | 488.75M |
| Date | Value |
|---|---|
| October 09, 2026 | 507.59M |
| October 08, 2026 | 500.24M |
| October 07, 2026 | 514.02M |
| October 06, 2026 | 501.16M |
| October 05, 2026 | 509.43M |
| October 02, 2026 | 512.18M |
| October 01, 2026 | 512.18M |
| September 30, 2026 | 517.69M |
| September 29, 2026 | 466.58M |
| September 28, 2026 | 449.23M |
| September 25, 2026 | 462.58M |
| September 24, 2026 | 471.47M |
| September 23, 2026 | 487.48M |
| September 22, 2026 | 548.86M |
| September 21, 2026 | 537.30M |
| September 18, 2026 | 548.86M |
| September 17, 2026 | 547.97M |
| September 16, 2026 | 501.71M |
| September 15, 2026 | 510.61M |
| September 14, 2026 | 533.74M |
| September 11, 2026 | 518.62M |
| September 10, 2026 | 534.63M |
| September 09, 2026 | 580.88M |
| September 08, 2026 | 619.13M |
| September 04, 2026 | 684.07M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Inovio Pharmaceuticals, Inc. | 116.48M |
| Capricor Therapeutics, Inc. | 448.71M |
| ACADIA Pharmaceuticals, Inc. | 2.335B |
| Alnylam Pharmaceuticals, Inc. | 21.50B |
| Anika Therapeutics, Inc. | 160.67M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -70.22M |
| Revenue (Quarterly) | 22.84M |
| Total Expenses (Quarterly) | 93.05M |
| EPS Diluted (Quarterly) | -0.7818 |
| Gross Profit Margin (Quarterly) | 98.38% |
| Profit Margin (Quarterly) | -307.4% |
| Earnings Yield | -42.45% |
| Normalized Earnings Yield | -45.52 |